About: How haemophilia A impacts severe acute respiratory syndrome coronavirus 2 (SARS-Cov-2) treatment: a case report

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: How haemophilia A impacts severe acute respiratory syndrome coronavirus 2 (SARS-Cov-2) treatment: a case report Goto Sponge NotDistinct Permalink

An Entity of Type : schema:ScholarlyArticle, within Data Space : wasabi.inria.fr associated with source document(s)

Attributes	Values
type	Academic Article research paper schema:ScholarlyArticle
isDefinedBy	Covid-on-the-Web dataset
has title	How haemophilia A impacts severe acute respiratory syndrome coronavirus 2 (SARS-Cov-2) treatment: a case report
Creator	Campello, Elena Luca Spiezia, · Pasca, Samantha Roberto Vettor, · Simioni, Paolo Zanon, Ezio
Source	Medline; PMC
abstract	The typical symptoms of COVID-19 mimic those of the common season flu. In addition, several changes in the coagulation processes have been observed. To date, it’s not fully clear how COVID-19 may affect patients with hereditary bleeding disorders. Anticoagulation in patients with haemophilia is still debated, but in this case could be needed. We are reporting a case of an elderly patient with mild haemophilia A hospitalized for Sars-Cov-2. On the 15th day of hospitalization, we observed an increase of all coagulation parameters. An antithrombotic prophylaxis at low dosage was immediately started, then increased at prophylactic dosage. Even if much more data are needed to ascertain the real thrombotic risk of haemophilia A in COVID-19 patients, it’s clear that the FVIII and vWF should be strictly monitored in order to promptly establish an adequate treatment and avoid the onset of thromboembolic events, even fatal, causing many deaths in COVID-19 patients.
has issue date	2020-07-16(xsd:dateTime)
bibo:doi	10.1007/s11239-020-02227-z
bibo:pmid	32676882
has license	no-cc
sha1sum (hex)	e841f2f80a8180de28f5766fa596f1a4bbc3c266
schema:url	https://doi.org/10.1007/s11239-020-02227-z
resource representing a document's title	How haemophilia A impacts severe acute respiratory syndrome coronavirus 2 (SARS-Cov-2) treatment: a case report
has PubMed Central identifier	PMC7364750
has PubMed identifier	32676882
schema:publication	J Thromb Thrombolysis
resource representing a document's body	covid:e841f2f80a8180de28f5766fa596f1a4bbc3c266#body_text
is schema:about of	named entity 'needed' named entity 'haemophilia A' named entity 'haemophilia' named entity 'thromboembolic events' named entity 'patients' named entity 'processes' named entity 'hospitalized' named entity 'How' named entity 'severe acute respiratory syndrome coronavirus 2 (SARS-Cov-2)' named entity 'SYMPTOMS' named entity 'PATIENTS' named entity 'HOSPITALIZATION' named entity 'NEEDED' named entity 'COULD BE' named entity 'ONSET OF' named entity 'REAL' named entity 'CLEAR' named entity 'REPORTING' named entity 'HAEMOPHILIA' named entity 'DEATHS' named entity 'ORDER' named entity 'coagulation' named entity 'mimic' named entity 'patient' named entity 'Anticoagulation' named entity 'prophylactic' named entity 'causing' named entity 'haemophilia A' named entity 'haemophilia' named entity 'haemophilia' named entity 'flu' named entity 'prophylactic' named entity 'thrombotic' named entity 'COVID' named entity 'prophylaxis' named entity 'case report' named entity 'haemophilia' named entity 'antigen' named entity 'polypectomy' named entity 'COVID' named entity 'thrombophilia' named entity 'fibrinogen' named entity 'SARS-CoV-2' named entity 'oxygen saturation' named entity 'infection' named entity 'VIII' named entity 'enoxaparin' named entity 'infection' named entity 'interstitial pneumonia' named entity 'COVID' named entity 'vWF' named entity 'IL-6' named entity 'chloroquine phosphate' named entity 'fibrinogen' named entity 'Intensive Care Unit' named entity 'tocilizumab' named entity 'antithrombotic' named entity 'D-dimer' named entity 'SARS' named entity 'Hubei Province' named entity 'antithrombotic' named entity 'adverse outcome' named entity 'thromboembolic complications' named entity 'high levels' named entity 'ICU' named entity 'coagulopathy' named entity 'high levels' named entity 'ICU' named entity 'prophylaxis' named entity 'enoxaparin' named entity 'haemorrhagic' named entity 'bleeding disorders' named entity '2, 3' named entity 'Coagulation' named entity 'Italian' named entity 'prophylaxis'

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2024 OpenLink Software